Literature DB >> 20845809

Protective effect of tetrandrine on doxorubicin-induced cardiotoxicity in rats.

Meng Xu1, Lianghe Sheng, Xinhai Zhu, Shibin Zeng, Dexiang Chi, Guo-Jun Zhang.   

Abstract

AIMS AND
BACKGROUND: Doxorubicin (Dox) is effective in curative and adjuvant chemotherapy of malignant tumors. Cardiotoxicity is the chief toxic effect that limits the clinical use of Dox. We studied the effects of tetrandrine (Tet) on doxorubicin-induced cardiotoxicity in rats and its protective activity.
MATERIALS AND METHODS: Sprague-Dawley rats were randomly divided into the following 4 groups: a control group (received only saline), Dox group (received only Dox), Tet/Dox group (received Tet plus Dox), and Tet group (received only Tet). Rats were injected intravenously with 2 mg/kg Dox once a week for 7 weeks and 50 mg/kg Tet was administered intraperitoneally weekly for 7 weeks. Measurements of cardiac contractile parameters including LSVP +dP/dt max and -dP/dt max, and assessment of electrocardiograms were carried out. Mitochondrial oxidation and phosphorylation state 3 (S3) and state 4 (S4) respiration were measured. Respiration control rate (RCR) and the ADP/O ratio were calculated. Cardiac ultrastructure was examined by electron microscopy.
RESULTS: Dox induced significant cardiotoxicity in this rat model. The values of LSVP, +dP/dt max, and -dP/dt max in the Tet/Dox group increased as compared to the Dox group (P <0.05). The cardiac contraction and relaxation improved on Tet administration. Tet inhibited the prolonged QT interval on the electrocardiogram in Dox-treated rats. Compared to the Dox group, the values of S3, RCR, and ADP/O increased by more than 28%, 48%, and 27%, respectively, in the Tet/Dox group. Significant cardiac morphological protection was observed in the Tet/Dox-treated rats.
CONCLUSION: Tet can improve the reduced cardiac function caused by Dox treatment and prevent Dox-induced mitochondrial impairment in rat cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20845809     DOI: 10.1177/030089161009600314

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  7 in total

1.  Acute adriamycin-induced cardiotoxicity is exacerbated by angiotension II.

Authors:  Eylem Taskin; Elvan Kunduz Kindap; Kalender Ozdogan; Mukerrem Betul Yerer Aycan; Nurcan Dursun
Journal:  Cytotechnology       Date:  2014-07-15       Impact factor: 2.058

2.  Lung cancer cellular apoptosis induced by recombinant human endostatin gold nanoshell-mediated near-infrared thermal therapy.

Authors:  Haiqing Luo; Meng Xu; Xinhai Zhu; Jianfu Zhao; Shiqing Man; Haoran Zhang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  Doxorubicin toxicity can be ameliorated during antioxidant L-carnitine supplementation.

Authors:  Othman A Alshabanah; Mohamed M Hafez; Mohamed M Al-Harbi; Zeinab K Hassan; Salim S Al Rejaie; Yosef A Asiri; Mohamed M Sayed-Ahmed
Journal:  Oxid Med Cell Longev       Date:  2010-11-01       Impact factor: 6.543

Review 4.  Mitochondria-Targeting Small Molecules Effectively Prevent Cardiotoxicity Induced by Doxorubicin.

Authors:  Wei Shi; Hongkuan Deng; Jianyong Zhang; Ying Zhang; Xiufang Zhang; Guozhen Cui
Journal:  Molecules       Date:  2018-06-19       Impact factor: 4.411

Review 5.  Progress on structural modification of Tetrandrine with wide range of pharmacological activities.

Authors:  Liuying Mo; Fan Zhang; Feng Chen; Lei Xia; Yi Huang; Yuemi Mo; Lingqiu Zhang; Daquan Huang; Shunli He; Jiagang Deng; Erwei Hao; Zhengcai Du
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

Review 6.  Cardioprotective Potentials of Plant-Derived Small Molecules against Doxorubicin Associated Cardiotoxicity.

Authors:  Shreesh Ojha; Hasan Al Taee; Sameer Goyal; Umesh B Mahajan; Chandrgouda R Patil; D S Arya; Mohanraj Rajesh
Journal:  Oxid Med Cell Longev       Date:  2016-05-23       Impact factor: 6.543

Review 7.  Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19.

Authors:  Paula M Heister; Robin N Poston
Journal:  Pharmacol Res Perspect       Date:  2020-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.